Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Atezolizumab (Tecentriq)

Published September 20, 2022

Key Messages

  • CADTH recommends that Tecentriq be reimbursed by public drug plans after surgery and chemotherapy for the treatment of patients with stage II to stage IIIA non–small cell lung cancer (NSCLC) whose tumour is positive for programmed death-ligand 1 (PD-L1) in at least 50% of tumour cells and does not have an abnormal EGFR or ALK gene if certain conditions are met.
  • Tecentriq should only be covered to treat adult patients (18 years or older) with stage II to stage IIIA NSCLC whose tumour is positive for PD-L1 in at least 50% of tumour cells and does not have an abnormal EGFR or ALK
  • Tecentriq should only be used alone after surgery and chemotherapy. Tecentriq should only be reimbursed if it prescribed by a specialist and if the patient is in relatively good health (i.e., has a good performance status, as determined by a specialist). Tecentriq should not be reimbursed if the patient is not a candidate for surgery or chemotherapy. The cost of Tecentriq must be lowered to be cost-effective and affordable.